Amla Cardiometabolic Randomized Trial Evidence Table

Structured evidence table for Amla Cardiometabolic Randomized Trial, generated from 1 reusable source document in the Migaku knowledge base.

topicclaimevidence levelcitationsource
Amla Cardiometabolic Randomized TrialDysregulation of this axis contributes to hypercholesterolemia and cardiometabolic risk, beyond classical cholesterol synthesis pathways.4Uberti F (2026)Natural Extract Combination Modulates Intestinal Barrier and Hepatic Cholesterol via the Gut-Liver Axis In Vitro.
Amla Cardiometabolic Randomized TrialIn HepG2 cells, MIX demonstrated synergistic effects: it reduced HMGR expression by 83-90% relative to individual extracts, increased LDLR expression by 43-97%, suppressed PCSK9 by up to 92%, and lowered total cholesterol and LDL uptake more effectively than RYRF.4Uberti F (2026)Natural Extract Combination Modulates Intestinal Barrier and Hepatic Cholesterol via the Gut-Liver Axis In Vitro.
Amla Cardiometabolic Randomized TrialMIX also amplified bile acid production and free cholesterol excretion, indicating improved hepatic clearance pathways.4Uberti F (2026)Natural Extract Combination Modulates Intestinal Barrier and Hepatic Cholesterol via the Gut-Liver Axis In Vitro.
Amla Cardiometabolic Randomized TrialBackground/Objectives: The gut-liver axis plays a central role in cholesterol homeostasis, linking intestinal absorption, microbial metabolites, and hepatic lipid regulation.4Uberti F (2026)Natural Extract Combination Modulates Intestinal Barrier and Hepatic Cholesterol via the Gut-Liver Axis In Vitro.
topicAmla Cardiometabolic Randomized Trial
claimDysregulation of this axis contributes to hypercholesterolemia and cardiometabolic risk, beyond classical cholesterol synthesis pathways.
evidence level4
citationUberti F (2026)
sourceNatural Extract Combination Modulates Intestinal Barrier and Hepatic Cholesterol via the Gut-Liver Axis In Vitro.
topicAmla Cardiometabolic Randomized Trial
claimIn HepG2 cells, MIX demonstrated synergistic effects: it reduced HMGR expression by 83-90% relative to individual extracts, increased LDLR expression by 43-97%, suppressed PCSK9 by up to 92%, and lowered total cholesterol and LDL uptake more effectively than RYRF.
evidence level4
citationUberti F (2026)
sourceNatural Extract Combination Modulates Intestinal Barrier and Hepatic Cholesterol via the Gut-Liver Axis In Vitro.
topicAmla Cardiometabolic Randomized Trial
claimMIX also amplified bile acid production and free cholesterol excretion, indicating improved hepatic clearance pathways.
evidence level4
citationUberti F (2026)
sourceNatural Extract Combination Modulates Intestinal Barrier and Hepatic Cholesterol via the Gut-Liver Axis In Vitro.
topicAmla Cardiometabolic Randomized Trial
claimBackground/Objectives: The gut-liver axis plays a central role in cholesterol homeostasis, linking intestinal absorption, microbial metabolites, and hepatic lipid regulation.
evidence level4
citationUberti F (2026)
sourceNatural Extract Combination Modulates Intestinal Barrier and Hepatic Cholesterol via the Gut-Liver Axis In Vitro.

Source documents

  1. Natural Extract Combination Modulates Intestinal Barrier and Hepatic Cholesterol via the Gut-Liver Axis In Vitro.